External trigeminal nerve stimulation for neuropsychiatric disorders: mechanisms, efficacy, and future directions.

Researchers reviewed studies on external trigeminal nerve stimulation (eTNS), a noninvasive treatment that uses small electrical currents applied to the forehead to influence brain activity. The trigeminal nerve connects the face to deep brain structures involved in mood, attention, and pain processing. This comprehensive review examined how eTNS works and its effectiveness across multiple neurological and psychiatric conditions. The strongest evidence supports eTNS for attention-deficit/hyperactivity disorder (ADHD) and migraine prevention, where patients showed meaningful clinical improvements. The treatment also shows promise as an add-on therapy for epilepsy and emerging potential for depression, anxiety, and consciousness disorders. eTNS appears safe with minimal side effects, making it an attractive option for patients who cannot tolerate medications or prefer drug-free approaches. However, the review identified important limitations: most studies involved small numbers of patients, short follow-up periods, and inconsistent treatment protocols, making it difficult to establish standardized guidelines. The electrical stimulation shares some similarities with electroacupuncture in that both use electrical currents to stimulate nerves and influence brain activity, though they target different anatomical locations. For patients with ADHD or migraines who haven't responded well to conventional treatments, eTNS may offer a promising alternative, though more rigorous research is needed to optimize treatment protocols and identify which patients are most likely to benefit. If you're interested in acupuncture or related neuromodulation approaches, consult with a qualified, licensed acupuncturist who can assess your individual needs.

This narrative review synthesizes clinical and mechanistic evidence for external trigeminal nerve stimulation (eTNS) across neuropsychiatric disorders. eTNS delivers low-intensity electrical currents to frontal trigeminal branches, modulating brain network activity in regions implicated in attention, mood regulation, and pain processing. The strongest clinical evidence supports efficacy in ADHD and migraine prophylaxis, with promising adjunctive benefits in epilepsy management. Emerging data suggest potential therapeutic applications for depression, anxiety, and consciousness disorders. The mechanism involves trigeminal-brainstem-cortical pathway modulation, similar in some respects to electroacupuncture's neuromodulatory effects. Methodological limitations include small sample sizes, heterogeneous stimulation parameters (frequency, intensity, duration), brief follow-up periods, and lack of standardized protocols. Safety profile is favorable with minimal adverse effects. Clinical takeaway: eTNS represents a promising noninvasive neuromodulation approach for treatment-resistant ADHD and chronic migraine, though practitioners should recognize current evidence limitations and the need for individualized parameter optimization. Future multicenter RCTs and biomarker-guided protocols are essential for clinical standardization.